Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicine for treating leukopenia and its preparing process

A leukopenia and drug technology, applied in the direction of drug combination, medical formula, extracellular fluid disease, etc., can solve the problems of patients with unobvious drug effect and slow drug effect

Inactive Publication Date: 2005-03-16
JILIN HUAYANG PHARMA
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above-mentioned drugs all have slow drug effects, and the drug effect is not obvious for individual patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0036] Experimental Example 1: Protective Effect of Shengbai Kangfu Oral Liquid on CTX-induced Hypoleukemia in Mice On the fifth day, CTX (80 mg / Kg) was injected intraperitoneally to form a hypoleukemia model, and the intragastric administration was continued until the eighth day, and blood was collected from the tail vein to determine the total number of white blood cells. The results are shown in Table 1.

[0037] Table 1 shows that each administration group of Shengbai Kangfu Oral Liquid can resist the reduction of white blood cells in mice caused by CTX, which is significantly different from the CTX group, and has no whitening effect on normal animals.

[0038] Table 1 protects against CTX-induced hypoleukemia in mice (X±SD)

[0039] Group Dose Number of animals Total number of white blood cells

[0040] (only) (1×10 9 / L)

[0041] Normal control 10 8.69±2.92

[0042] CTX 80mg / Kg 10 2.60±0.56 △△

[0043] CTX+ Shengbai Kangfu Oral Liqui...

experiment example 2

[0051] Experimental Example 2: Shengbai Kangfu Oral Liquid 60 Protective effect of hypoleukemia in mice induced by Co irradiation

[0052] mice with 60 After one-time Co irradiation (dose 4.5GY), they were divided into groups according to Table 2 and administered by intragastric administration for seven consecutive days. Blood was collected from the tail vein on the eighth day to determine the total number of white blood cells. The results are shown in Table 2.

[0053] Table 2 shows that each administration group of Shengbai Kangfu Oral Liquid can make 60 The leukopenia caused by Co was obviously picked up, and 60 There was a significant difference between the Co injury group.

[0054] Table 2 pairs 60 Protective effect on hypoleukemia in mice induced by Co irradiation ( X±SD)

[0055] Group Dose Number of animals Total number of white blood cells

[0056] (only) (1×10 9 / L)

[0057] Normal control 10 10.08±21.26

[0058] 60 Co d...

experiment example 3

[0064] Experimental Example 3: Effect of Shengbai Kangfu Oral Liquid on the Phagocytosis of Immune Organs and Reticuloendothelial System (RES)

[0065] The mice were randomly divided into groups according to Table 4, and the animals in each group were given intragastric administration for eight days. Except for the control group, CTX 10 mg / Kg was injected from the fourth day to the eighth day, and 1 hour after the last administration, at Inject the diluted Yidege ink 10mg / Kg into the tail vein of the mouse, then collect 0.05ml blood from the orbital vein of the mouse 2min and 15min later, dissolve it in 5ml0.1%Na 2 CO 3 In the solution, colorimetric at 650nm, calculate the phagocytosis index K and phagocytosis coefficient a, and calculate the visceral index of thymus, spleen and liver. The results are shown in Tables 3 and 4.

[0066] Table 3 shows that in the case of low immune function after giving CTX, giving Shengbai Kangfu Oral Liquid has a very significant activation e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating leukopenia and its preparing process, wherein the medicine is prepared from astragalus root, acanthopanax root, gen-seng, white atractylodes rhizome, prepared rehmannia root, donkey-hide gelatin, fleece-flower root, Ligusticum wallichii1, Poria cocos, immature bitter orange and Chinese angelica root through the steps of extracting and filtering.

Description

technical field [0001] The invention relates to a medicine for treating leukopenia and a preparation method thereof, belonging to the technical field of Chinese patent medicines. Background technique [0002] Leukopenia is a major problem in radiotherapy and chemotherapy for malignant tumor patients. Clinically, the number of leukocytes in the blood is often reduced, and the treatment is often forced to be terminated, thereby reducing the quality of life of the patient and the treatment effect of the doctor; the current domestic market for the treatment of leukopenia Her medicines include "Compound Zaofan Pills", "Shenqi Granules" and "Shiwei Fuzheng Granules". From the perspective of the functions and indications of the main components of the prescription, each has its own characteristics. Compound Zaofan pills are mainly composed of saponin, American ginseng, hippocampus, cinnamon, jujube, and walnut kernel. It is mainly used to warm the kidney and strengthen the spleen, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P7/00A61P35/00
Inventor 张广学刘德顺张福营
Owner JILIN HUAYANG PHARMA
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com